Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: BRCA1 Gene Mutation|BRCA2 Gene Mutation|Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma
Interventions: DRUG: Carboplatin|OTHER: Fluorothymidine F-18|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|PROCEDURE: Positron Emission Tomography|DRUG: Veliparib
Sponsor: National Cancer Institute (NCI)